secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002247
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia closes $75M PIPE, draws $25M debt facility, files counterclaims in UTHR patent suit
--------------------------------------------------------------------------------

- Closed private placement of 7.18M shares at $10.442/share for ~$75M gross proceeds; additional $25M drawn under revenue interest financing amendment.
- Filed response to UTHR patent suit seeking dismissal of invalidated '793 patent claims and asserting counterclaims that '327 patent is invalid due to undisclosed prior art.
- Enrolled first PH-ILD patient in YUTREPIA ASCENT study; PDUFA date for tentative approval is Jan 24, 2024.
- FDA agreed that single Phase 3 trial of L606 in PH-ILD will support both PAH and PH-ILD indications; global study to start later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924002247/0001104659-24-002247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924002247/tm242158d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer